This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Since the first implementation in 2002 by Alain Cribier, transcatheter aorticvalve replacement (TAVR) has become a standard procedure for high-risk and elderly patients with severe aorticvalvestenosis. On the other hand, TAVR patients are older, have. 1 Its incidence, reported as 1.1%
Transcatheter aorticvalve replacement (TAVR) has become a leading treatment for aorticstenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.
Data shows, versus surgery, the Evolut transcatheter aorticvalve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Evolut TAVR vs. 9.3% Evolut TAVR vs. 9.3% Grubb, M.D., 1 Herrmann H.
(MedPage Today) -- Transcatheter aorticvalve replacement (TAVR) yielded clinical benefit when given early in the disease process while patients still had no symptoms or other indication for aorticvalve replacement, according to the EARLY TAVR.
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aorticvalve system (Xcor system, Saint Medical Technology, Inc.,
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aorticvalve replacement (SAVR) for patients under age 65 with severe aorticstenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Transcatheter aorticvalve replacement (TAVR) is the standard treatment for severe aorticstenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aorticvalve complex.
IntroductionSince TAVR was approved for lower-risk aorticstenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).
Background Subclinical leaflet thrombosis (SLT) is a common complication after transcatheter aorticvalve replacement (TAVR). Methods This prospective cohort study consecutively enrolled patients with severe symptomatic aorticstenosis who underwent successful TAVR.
AorticStenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aorticvalve replacement was the primary treatment option for severe AS for decades.
Valvular heart disease, including calcific or degenerative aorticstenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aorticvalve replacement (TAVR).
Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program recently reported it has reached a significant milestone of performing over 5,000 transcatheter aorticvalve replacement (TAVR) procedures, the first in New Jersey and among the first to accomplish this in the United States.
Some patients with aorticstenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aorticvalve replacement (TAVR) as the initial intervention may be appealing to many. If their transcatheter heart valve degenerates later in life, most will hope to undergo redo-TAVR.
Objectives The clinical outcomes of transcatheter aorticvalve replacement (TAVR) in patients with aorticstenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer. vs 74.7%, p=0.50).
What is the 5-year incidence of valve reintervention after self-expanding CoreValve/Evolut transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR)?
The goal of the EARLY TAVR trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with clinical surveillance among patients with asymptomatic severe aorticstenosis (stage C aorticstenosis).
Transcatheter aorticvalve replacement (TAVR) has increased in utilization since its approval for management of aorticstenosis patients across all risk strata. We report a rare case of aorticvalve leaflet av.
IntroductionClinical evidence highlighting the efficacy and safety of transcatheter aorticvalve replacement (TAVR) and the 2019 Food and Drug Administration (FDA) approval for TAVR in low-risk (younger) patients has created a demand for durable and long-lasting bioprosthetic heart valve (BHV) leaflet materials.
What are the hemodynamic and clinical outcomes after transcatheter aorticvalve replacement (TAVR) and surgical aorticvalve replacement (SAVR) among patients with severe aorticstenosis (AS) and a small aortic annulus?
Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aorticvalve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates.
The goal of the NOTION trial was to compare outcomes after transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR) in unselected patients with severe degenerative aorticstenosis.
Transcatheter aorticvalve replacement (TAVR) is a relatively new treatment method for aorticstenosis (AS) and has been demonstrated to be suitable for patients with varying risk levels.
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aorticvalve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aorticstenosis (AS).
The goal of the VIVA trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with surgical aorticvalve replacement (SAVR) among patients with severe aorticstenosis and a small aortic annulus.
Objective A novel artificial intelligence-based phenotyping approach to stratify patients with severe aorticstenosis (AS) prior to transcatheter aorticvalve replacement (TAVR) has been proposed, based on echocardiographic and haemodynamic data. after TAVR, were available from 247 patients (67.5%).
(MedPage Today) -- NEW YORK CITY -- With valve-in-valve procedures becoming a key concern for patients with aorticstenosis, familiar transcatheter aorticvalve replacement (TAVR) devices are being tweaked to facilitate future operations that.
The goal of the TAVR UNLOAD trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with clinical surveillance among patients with chronic systolic heart failure and moderate aorticstenosis (stage B aorticstenosis).
This concept should be applied when managing older patients with severe aorticstenosis. Although left ventricular wall hypertrophy is expected in patients with aorticstenosis, it should not be assumed that this is caused only by aorticstenosis.
Two separate late-breaking clinical trials – EARLY TAVR and EVOLVED – presented at TCT 2024 explore whether early aorticvalve intervention improves outcomes in patients with asymptomatic aorticstenosis (AS).
If you’ve been diagnosed with aorticstenosis, you might have come across the term TAVR. If you’re wondering “ What is TAVR ?” Understanding AorticStenosis The aorticvalve regulates blood flow from your heart’s main pumping chamber to the rest of your body. Who Is a Candidate for TAVR?
The first powered randomized trial examining early intervention with transcatheter aorticvalve replacement (TAVR) in patients with asymptomatic, severe aorticstenosis (AS) found this strategy to be both a safe and effective alternative to clinical surveillance (CS).
A nationwide observational analysis of patients with aorticstenosis (AS) and cardiogenic shock (CS) who underwent transcatheter aorticvalve replacement (TAVR) or surgical aorticvalve replacement (SAVR) determined that patients who underwent TAVR had lower in-hospital complications and resource utilization compared with SAVR.
Hunter Mehaffey, MD, a cardiothoracic surgeon from West Virginia University, will examine results comparing two treatment options Transcatheter vs. Surgical AorticValve Replacement in Medicare Beneficiaries with AorticStenosis and Significant Coronary Disease.
American College of Cardiology/American Heart Association guideline recommendations for transcatheter aorticvalve replacement (TAVR) transitioned in 2020 from decision-making based on estimated risk of surgical valve replacement (SAVR) to one based on patient age and expected longevity.
Transcatheter aorticvalve replacement (TAVR) is increasing in popularity for symptomatic severe aorticstenosis. Transfemoral arterial route is the most commonly used approach for TAVR, also known as TAVI or transcatheter aorticvalve implantation. JACC: Asia. May 14, 2024. 2024.03.006
What are clinical outcomes among patients with severe aorticstenosis (AS) and coronary artery disease (CAD) undergoing surgical aorticvalve replacement (SAVR) plus revascularization versus transcatheter aorticvalve replacement (TAVR) plus percutaneous coronary intervention (PCI)?
Transcatheter aorticvalve replacement (TAVR) has increasingly become a safe, feasible, and widely accepted alternative surgical treatment for patients with severe symptomatic aorticstenosis.
TAVR in heart failure. ABSTRACT Patients with severe aorticstenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear.
Transcatheter aorticvalve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Reintervention for failed transcatheter heart valves will likely increase in the future as younger patients are expected to outlive the initial bioprosthesis.
Background Increase in left ventricular filling pressure (FP) and diastolic dysfunction are established consequences of progressive aorticstenosis (AS). However, the impact of elevated FP as detected by pretranscatheter aorticvalve replacement (TAVR) echocardiogram on long-term outcomes after TAVR remains unclear.
The goal of the SOLVE-TAVI trial was to compare the safety and efficacy of the Edwards Sapien S3 valve vs. Medtronics CoreValve among patients undergoing transcatheter aorticvalve replacement (TAVR) for severe aorticstenosis.
Objectives To understand the patient and hospital level drivers of the variation in surgical versus trascatheter aorticvalve replacement (SAVR vs TAVR) for patients with aorticstenosis (AS) and to explore whether this variation translates into differences in clinical outcomes.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content